SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Key Highlights
- ➤Worldwide revenue $55.7M, up 14.5% year over year
- ➤Adjusted EBITDA $3.0M, up 32.4% year over year
- ➤2026 revenue guidance reaffirmed at $231M-$233M
- ➤Operating expense growth outlook reduced to 10.5% at revenue midpoint
- ➤iFuse Granite Onyx receives FDA 510(k) clearance targeting a ~$1.5B annual market
Expert Statements
Laura Francis, Chief Executive Officer of SI-BONE
“Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technologies.”
Laura Francis, Chief Executive Officer of SI-BONE
“We enter the fourth quarter with a record number of active physicians, favorable DRG changes and exceptional early uptake in our alpha launch of iFuse Granite Onyx, our new platform technology that expands our estimated total addressable market to approximately $5 billion.”
Laura Francis, Chief Executive Officer of SI-BONE
“These drivers position us for an excellent finish to 2026 and enter 2027 with the strongest foundation for growth acceleration in our company's history.”
Delivered ~20% U.S. procedure volume growth in the third quarter
Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) * Worldwide revenue of $55.7 million, representing growth of 14.5% * U.S. revenue of $52.8 million, representing growth of 13.9% * Gross margin of 79.3% * Net loss of $3.6 million, representing an improvement of 20.7% * Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4% * Positive cash from operations of $5.9 million, representing an improvement of 154.4% * $146.3 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) * 1,770 active U.S. physicians, representing growth of ~16% * In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually * In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.